Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

Study limitation reported by the research below: “OS data are immature at time of publication — the primary PFS endpoint was met but OS did not reach statistical significance; final OS analysis is ongoing.”